BRAIN Biotech AG Elevator Pitch: Key Takeaways

BRAIN Biotech AG: Elevator Pitch from CFO Michael Schneiders

A Pioneer in Sustainable Industrial Biotechnology

In this compelling elevator pitch from CFO Michael Schneiders of BRAIN Biotech AG, headquartered in Zwingenberg, Germany, the company positions itself as a pioneer in sustainable industrial biotechnology, utilising nature as a blueprint to tackle some of the world’s most pressing industrial production challenges.

Biotechnological Innovation for Global Challenges

BRAIN applies biotechnological principles to improve the efficiency, sustainability, and health impact of industrial production, especially in food, beverage, and life sciences. Its innovations include enzyme solutions that contribute to energy savings, alternative proteins that reduce the need for monocultures and livestock farming, and bio-based ingredients, all of which contribute to global food security and well-being.

Two Core Business Divisions

The company operates via two core divisions:

BRAIN Biocatalysts

A commercial products division generating approx. €47.5 million in annual revenues and €5.1 million in adjusted EBITDA. It focuses on enzymes, microorganisms, and bio-based ingredients used widely in processed food and other industrial applications. The segment is profitable, maintains a strong 5% R&D investment ratio, and aims to reach €100 million in sales with a 15% adjusted EBITDA margin in the medium term, demonstrating strong revenue growth.

BRAIN BioIncubator

The innovation arm is dedicated to incubating high-potential biotech projects, primarily in the space of food, beverage and pharmaceuticals. Last year, it generated €7.1 million in revenue. It is central to the company’s long-term value creation strategy, with a focus on monetising breakthrough technologies and entering high-margin licensing partnerships.

Fully Integrated Enzyme Solutions Provider

BRAIN is a fully integrated enzyme solutions provider covering the entire value chain:

- Discovery (in nature or via own engineering)

- Strain development and expression (bacteria, fungi, or yeast-based bio-factories)

- Fermentation (industrial-scale in Cardiff)

- Enzyme formulation and global distribution

Three Go-to-Market Channels

The company serves customers via three go-to-market channels:

- Product sales: Especially to the food & beverage sectors (dairy, baking, wine, starch)

- Contract research: Custom R&D for client-specific solutions

- Contract development and manufacturing (CDMO): Supporting client bioprocess optimisation and industrial fermentation

High-Value BioIncubator Projects

CFO Schneiders highlights two high-value BioIncubator projects now being commercialised:

Royalty Pharma Transaction

BRAIN monetised early-stage rights to an investigative pharmaceutical compound, securing €18.4 million upfront with potential total proceeds of up to €138 million.

▶️ Other videos:

Elevator Pitch: https://seat11a.com/investor-relations-elevator-pitch/

Company Presentation: https://seat11a.com/investor-relations-company-presentation/

Deep Dive Presentation: https://seat11a.com/investor-relations-deep-dive/

Financial Results Presentation: https://seat11a.com/investor-relations-financial-results/

ESG Presentation: https://seat11a.com/investor-relations-esg/

📲 Follow seat11a:

🔗 Website: https://seat11a.com

📢 LinkedIn: https://www.linkedin.com/company/seat11a

🐦 Twitter: https://x.com/seat11a_com

🎧 Spotify: https://open.spotify.com/show/1XXbzcQmY3fbeeoodYIO0H

T&C

This publication is intended solely for informational purposes and does not constitute investment advice. By using this website, you agree to our terms and conditions as outlined on www.seat11a.com/legal and www.seat11a.com/imprint.